Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

This systematic review and meta-analysis evaluated the efficacy and safety of non-steroidal antiandrogen (NSAA) monotherapy compared to luteinising hormone-releasing hormone (LHRH) agonists or surgical castration in advanced prostate cancer. The study found that NSAA monotherapy was associated with a higher risk of death (HR 1.25, 95% CI 1.05-1.48), increased clinical